The criticality of supply chain resilience has become increasingly apparent in recent years, including for essential medicines and health products. The COVID-19 pandemic and geopolitical tensions have highlighted certain vulnerabilities of global supply chains, particularly in the areas of raw materials, manufacturing, transportation, and logistics. Early in COVID 19 pandemic, widespread disruption of global trade created challenges for the uninterrupted supply of essential medicines, underscoring the importance of uniform support for resilient global supply chains.

IGBA informs that Jonathan Kimball is no longer part of the staff of the Association for Accessible Medicines (AAM), our U.S. IGBA Member, and hence, is no longer in the position as IGBA Chair. Subsequently, David Gaugh, AAM's Interim CEO, has taken up the Director role for AAM on the IGBA Management Committee. To ensure continuity, IGBA is very pleased to announce that the IGBA Management Committee has unanimously nominated David Gaugh as the new IGBA Chair for the rest of 2023. David has been involved within IGBA since 2012, and was previously the IGBA Chair in 2014, where he lead the then Alliance to be legalized under Swiss law to become the Association. David again chaired the IGBA in 2018.

IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that experts and leaders from the local and global generic and biosimilar medicines industries, Government and regulatory agencies, academia and other stakeholders are meeting from 15 to 16 February in Orlando, Florida to discuss key topics affecting worldwide patient access to affordable quality-assured medicines, such as...